Literature DB >> 10574998

Characterization of the amino-terminal activation domain of peroxisome proliferator-activated receptor alpha. Importance of alpha-helical structure in the transactivating function.

R Hi1, S Osada, N Yumoto, T Osumi.   

Abstract

The transactivating function of the A/B region of mouse peroxisome proliferator-activated receptor alpha (PPARalpha; NR1C1) was characterized. The truncated version of PPARalpha lacking the A/B region had 60-70% lower transactivating function than full-length PPARalpha in both the presence and absence of the peroxisome proliferator ciprofibrate. When tethered to the yeast Gal4 DNA-binding domain, the A/B region exhibited the significant ligand-independent transactivating function, AF-1 activity. The first 44 amino acid residues were necessary for maximal transactivation, and the minimally essential region was further delimited to amino acids 15-44. This region is highly enriched with acidic residues, but mutational analyses showed that the protein structure, rather than the negative charge itself, was important for the AF-1 activity. An alpha-helical configuration was predicted for this region, and a CD spectrum analysis of the synthetic peptides showed that mutant sequences with higher AF-1 activity have higher helical contents and vice versa. The most active mutant, in which Met(31) was replaced with Leu, was approximately 5-fold more potent than the wild-type A/B region. These findings indicate that the AF-1 region of PPARalpha is an acidic activation domain and that the helix-forming property is implicated in the transactivating function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574998     DOI: 10.1074/jbc.274.49.35152

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  The role of PPARα in autosomal dominant polycystic kidney disease.

Authors:  Ronak Lakhia
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 2.894

2.  A small ubiquitin-related modifier-interacting motif functions as the transcriptional activation domain of Krüppel-like factor 4.

Authors:  James X Du; Beth B McConnell; Vincent W Yang
Journal:  J Biol Chem       Date:  2010-06-28       Impact factor: 5.157

3.  Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators.

Authors:  G Lazennec; L Canaple; D Saugy; W Wahli
Journal:  Mol Endocrinol       Date:  2000-12

4.  Aspects of the regulatory mechanisms of PPAR functions: analysis of a bidirectional response element and regulation by sumoylation.

Authors:  Makoto Shimizu; Daisuke Yamashita; Tomohiro Yamaguchi; Fumiko Hirose; Takashi Osumi
Journal:  Mol Cell Biochem       Date:  2006-03-14       Impact factor: 3.396

5.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

6.  The PPARgamma2 A/B-domain plays a gene-specific role in transactivation and cofactor recruitment.

Authors:  Anne Bugge; Lars Grøntved; Mads M Aagaard; Rehannah Borup; Susanne Mandrup
Journal:  Mol Endocrinol       Date:  2009-03-12

Review 7.  Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.

Authors:  Philippe Lefebvre; Giulia Chinetti; Jean-Charles Fruchart; Bart Staels
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

8.  MEK1 inhibits cardiac PPARα activity by direct interaction and prevents its nuclear localization.

Authors:  Hamid el Azzouzi; Stefanos Leptidis; Meriem Bourajjaj; Marc van Bilsen; Paula A da Costa Martins; Leon J De Windt
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

9.  Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation.

Authors:  Anne Bugge; Susanne Mandrup
Journal:  PPAR Res       Date:  2010-08-31       Impact factor: 4.964

10.  NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.

Authors:  Yaru Li; Mingming Chen; Yu Zhou; Chuanfeng Tang; Wen Zhang; Ying Zhong; Yadong Chen; Hong Zhou; Liang Sheng
Journal:  Theranostics       Date:  2020-02-18       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.